Prapela
Neonatal-device startup commercializing an FDA-authorized stimulation therapy for opioid-exposed newborns and other infant respiratory problems.
What They Do
Prapela's lead product is the SVS hospital bassinet pad, which delivers stochastic vibrotactile stimulation as an adjunctive non-pharmacologic therapy for newborns with neonatal opioid withdrawal syndrome (NOWS). The company positions the device as hospital-ready and designed for NICUs, step-down units, and general newborn units, where it can extend Eat-Sleep-Console style care when caregivers cannot continuously hold or console the infant. Prapela is also developing incubator-pad applications for apnea and hypoxia in newborns, which gives it a broader neonatal-respiratory wedge beyond opioid withdrawal. The commercial model is provider-facing medical-device sales into hospitals rather than payer- or consumer-led distribution.
Competitive Position
Prapela competes less with digital-health newborn care companies and more with standard hospital supportive care, nurse workflow, and a small set of device alternatives touching motion, soothing, and respiratory stability in infants. Its differentiation is regulatory: the company now has FDA De Novo authorization tied to a specific neonatal indication rather than offering a generic bassinet or wellness device. If Prapela can prove operational savings and scale hospital adoption, it could become a meaningful therapeutic-device layer inside the NICU and newborn-nursery workflow.
Funding Rounds
No funding rounds on record for this company.